← All trials
NCT04031066
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 25, 2020
- Primary completion
- Mar 15, 2021
- Completion date
- Mar 29, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 12
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- ChiesiLead sponsor
- University of California, San FranciscoOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.